Siglec-6 is a target for chimeric antigen receptor T-cell treatment of chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

Siglec-6 is a target for chimeric antigen receptor T-cell treatment of chronic lymphocytic leukemia

Published:2021-02-25 Issue:9 Volume:35 Page:2581-2591
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Kovalovsky Damian^ORCID,Yoon Jeong Heon,Cyr Matthew G.,Simon Samantha,Voynova Elisaveta,Rader Christoph^ORCID,Wiestner Adrian,Alejo Julie,Pittaluga Stefania,Gress Ronald E.

Funder

U.S. Department of Health & Human Services | NIH | National Cancer Institute

Bench to bedside and back program. Office of clinical Research, NIH

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/s41375-021-01188-3.pdf

Reference25 articles.

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352:804–15.

2. Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG, et al. Chronic lymphocytic leukaemia. Nat Rev Dis Prim. 2017;3:17008.

3. Wiestner A. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia. Haematologica. 2015;100:1495–507.

4. Ahn IE, Underbayev C, Albitar A, Herman SE, Tian X, Maric I, et al. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood. 2017;129:1469–79.

5. Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370:2286–94.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Siglec-6 as a therapeutic target for cell migration and adhesion in chronic lymphocytic leukemia;Nature Communications;2024-06-18

2. Unveiling immune tolerance pathways in preeclampsia placenta: implications for molecular targets and discovery of potential biomarkers;Frontiers in Endocrinology;2024-06-04

3. Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma;Frontiers in Oncology;2024-04-22

4. Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk;Clinical Cancer Research;2024-03-06

5. The Potential of Siglecs and Sialic Acids as Biomarkers and Therapeutic Targets in Tumor Immunotherapy;Cancers;2024-01-10